Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation
"Frontier
Pharma: Breast Cancer - Identifying and Commercializing
First-in-Class Innovation"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Exceptionally
Large and Innovative Pipeline
The
breast cancer pipeline is the largest in the pharmaceutical industry
with 815 products in active development across all stages. The range
of mechanisms of action employed by these compounds is also highly
diverse, especially in comparison to the existing market landscape.
More pertinently, the degree and proportion of breakthrough
innovations in this pipeline is exceptional;
GBI
Research analysis identified 253 first-in-class programs in the
breast cancer pipeline, acting on 176 first-in-class molecular
targets. This accounts for some 39% of all products with a disclosed
molecular target and is reflective of the high degree of innovation
in this indication. This has far-reaching strategic implications for
all market participants, as, despite the high attrition rate in
breast cancer, it is highly likely many of the first-in-class
technologies will reach the market over the coming decade and may
transform the clinical and commercial landscape.
Alignment
of First-in-Class Molecular Target with Disease Causation
One
of the key trends in oncology and in breast cancer in particular over
the last decade is the clinical and commercial impact of targeted
therapies designed to target proteins in signaling pathways that are
frequently mutated in a significant proportion of the patient
population. By aligning the molecular targets for therapeutic
intervention with disease causation and/or propagation, these
therapies limit the systemic cytotoxic effects whilst inhibiting
tumor-promoting signaling pathways. Such strategies thereby typically
achieve superior efficacy and safety profiles.
Our
proprietary analyses demonstrate significant levels of
differentiation as to how well the first-in-class products and their
respective molecular targets align to underlying gene and protein
level mutations and dysfunction. More advanced analytics further
substantiated these findings as strong levels of differentiation in
the scientific and clinical rationale for first-in-class molecular
targets emerged. Furthermore, clear frontrunners were identified by
integrating analyses to assess the accessibility of molecular targets
for therapeutic compounds, the size of the target patient population
that would benefit from therapeutic intervention, and the expected
positioning of the first-in-class products based on the molecular
targets and mechanisms of action of currently marketed products.
Table
of Contents
1
Table of Contents
1
Table of Contents 2
1.1
List of Tables 3
1.2
List of Figures 3
2
Executive Summary 4
2.1
Exceptionally Large and Innovative Pipeline 4
2.2
Alignment of First-in-Class Molecular Target with Disease Causation 4
2.3
A Highly Active Deals Landscape with Numerous Investment
Opportunities 4
3
The Case for Innovation in the Breast Cancer Market 5
3.1
Growing Opportunities for Biologic Products 5
3.2
Diversification of Molecular Targets 5
3.3
Innovative First-in-Class Product Developments Remain Attractive 5
3.4
Changes in the Clinical and Commercial Environment to be More
Favorable to Products Targeting Niche Patient Populations and
Indications 6
3.5
Sustained Innovation 6
3.6
Report Guidance 6
4
Clinical and Commercial Landscape 8
4.1
Disease Overview 8
4.2
Disease Symptoms 8
4.3
Etiology 8
4.4
Pathophysiology 9
4.4.1
Tumor Initiation, and Aberrant Cell Proliferation and Survival 10
4.4.2
Tumor Metabolic Shift 11
4.4.3
Tumor Progression, Microenvironment Alteration and Angiogenesis 11
4.4.4
Cancer Stem Cells 12
4.5
Diagnosis 13
4.6
Prognosis and Disease Staging 13
4.6.1
Classification 14
4.7
Introduction to Breast Cancer Treatments 15
4.8
Surgery and Radiation Therapy 16
4.9
Overview of Marketed Products for Breast Cancer 16
4.9.1
Chemotherapy 17
4.9.2
Efficacy of Chemotherapy Regimens 18
4.9.3
Hormonal Therapies 20
4.9.4
Efficacy of Endocrine Therapies 20
4.9.5
Targeted Therapies 22
4.9.6
Efficacy of Targeted Therapies 23
Comments
Post a Comment